



CEO presentation to the AGM

Dr Ken Taylor

18 November 2014

<http://www.lctglobal.com>

Safe Harbour Statement



This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates.

Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.

There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales.

In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects.

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

LCT is providing this information as of the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

Milestones achieved in 2014

- Resumed NTCELL clinical trial
- Regained 100% ownership of NTCELL
- Finalised QA/CT SOPs/GCP
- Completed recruitment of all four patients for Parkinson's disease trial
- Scientific advisors appointed: Roger Barker (Cambridge, UK), Richard Faull (Auckland, NZ), Anne Young (Harvard, US)
- Collaboration agreement with Centre for Brain Research, Auckland
- Raised A\$3M through high quality investors from New Zealand
- Secured OPF financing of DOL joint venture
- Streamlined IP portfolio and patent strategies
- Initiated grant applications for non-dilutive financing

NTCELL Phase I/IIa clinical trial team



Living Cell Technologies

Ken Taylor, PhD

LCT CEO

Kathleen Durbin, PhD

Clinical and Regulatory Manager

Jenny Han, BPharm Hons

Clinical Trials Officer

Michelle Lockhart, PhD

Head of Quality Assurance

Auckland Clinical Site

Barry Snow, MBChB, FRACP

Principal Investigator, Neurologist

Mark Simpson,

Investigator, Neurologist

Ari Bok, MBChB, FRACS

Neurosurgeon

**Lorraine Macdonald, RGON,
BHSc (Nsg) Study Nurse**

DSMB

*Prof Tim Anderson (Neurologist,
Chair); Dr Rod Ellis-Pegler (ID); Dr
Andrew Hughes (Neurologist)*

Scientific Advisors

Anne B Young, MD

*Professor of Neurology, Harvard
Medical School, Boston, USA*


Roger Barker, MD

*Professor of Clinical Neurosciences
and Deputy Director, John van
Geest Centre for Brain Research,
University of Cambridge, UK*

Richard Faull, MBChB, PhD

*Professor of Anatomy and Director,
Centre for Brain Research,
University of Auckland, NZ*

Clinical trial timeline: NTCELL for Parkinson's disease






What is NTCELL?

Jackie Lee, PhD



Head of Research & Development

Brain: ventricles, CSF and choroid plexus

Front view









Side view



Choroid Plexus:

- Secretes cerebrospinal fluid (CSF)
- Provides neurotrophic factors
- Provides neuroprotective factors
- Removes toxin (drugs, metals, etc.)
- Clears waste products

NTCELL: Encapsulated neonatal porcine choroid plexus






Nigrostriatal dopaminergic activation: in healthy vs. Parkinson's brains




Healthy brain

Parkinson's disease

+ NTCELL



NTCELL implantation into the putamen of Parkinson's patients





Pipeline projects: collaboration with Centre for Brain Research


Prof Richard Faull

Director

Centre for Brain Research



- 59 different research groups
 - Clinical researchers
 - Cognitive neuroscientists
 - Molecular and cellular neuroscience
 - Sensory and motor neuroscience
 - Imaging specialists
- More than 350 researchers
- Neurological Foundation Human Brain Bank
- Hugh Green Trust Biobank
- Brain Recovery Clinic (stroke and dementia)
- NeuroDiscovery platforms



A Foundation of International Expertise and Collaboration



Opportunity: Neurodegenerative Disorders



- Parkinson's disease (PD)
 - Estimated 7-10 million people worldwide are living with PD
 - Incidence increases with age; 4% of Parkinson's patients are diagnosed before 50 years
- Huntington's disease (HD)
 - Up to 490,000 people worldwide may be affected by HD
 - Up to 1.7 million may have a 50% risk of developing HD
- Alzheimer's disease (AD)
 - Estimated at least 26 million people worldwide have AD
 - Incidence increases with age; high care-giver burden
- Research opportunities
 - Determine methods to delay the onset and minimise effects of neurodegeneration
 - Identify mechanisms of neuroplasticity and enhance recovery
 - Test research results in research clinics and roll out to community



Increasing shareholder value

Ken Taylor, PhD

Chief executive

Movement Disorder Society of Australia



2014 conference, 18-19 August 2014


Advanced therapies for Parkinson's disease:

- Deep brain stimulation
- Duo-dopa (jejenum implant)
- Apomorphine brain implant

Conclusions: Advanced therapies accepted as the future for Parkinson's treatment, but expensive (>USD100,000); short-term improvement; on-going maintenance; early intervention provides best responses.



Movement Disorder
SOCIETY OF AUSTRALIA



**International Parkinson and
Movement Disorder Society**

Presentation of Phase I/IIa clinical trial results



The dates below are given as a guide only

- 8 January 2015: Abstract submitted
- 30 May 2015: Scientific advisors (Prof Roger Barker, Prof Richard Faull and Prof Anne Young) review results
- 14-18 June 2015: Barry Snow to present results of trial at the 19th International Congress of Parkinson's Disease and Movement Disorders

19TH INTERNATIONAL CONGRESS OF PARKINSON'S
DISEASE AND MOVEMENT DISORDERS

JUNE 14-18

2015

SAN DIEGO, CA, USA

